Table of Content


Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Base estimates and working
1.3 Forecast calculations
1.4 Data sources
1.4.1 Primary
1.4.2 Secondary
1.4.2.1 Paid sources
1.4.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Global primary care POC diagnostics market 360 degree synopsis, 2018 – 2032
2.1.1 Regional trends
2.1.2 Product trends
2.1.3 End-use trends
Chapter 3 Primary Care POC Diagnostics Industry Insights
3.1 Industry ecosystem analysis
3.2 Technology landscape
3.3 Regulatory landscape
3.4 Industry impact forces
3.4.1 Growth drivers
3.4.1.1 Upward trend in disease prevalence and demand for quick diagnostics
3.4.1.2 Technological advancements in POCT devices
3.4.1.3 Increasing R&D investment
3.4.2 Industry pitfalls and challenges
3.4.2.1 Stringent regulatory framework
3.4.2.2 High cost of product development
3.5 Growth potential analysis
3.5.1 By product
3.5.2 By end-use
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis, 2023
4.3 Competitive analysis of major market players, 2023
4.4 Competitive positioning matrix, 2023
4.5 Strategic outlook matrix, 2023
Chapter 5 Primary Care POC Diagnostics Market Size and Forecast, By Product, 2018-2032 (USD Million)
5.1 Key trends, by product
5.2 Glucose monitoring
5.3 Cardiometabolic testing products
5.3.1 Cardiac marker testing products
5.3.1.1 hsTnl
5.3.1.2 BNP
5.3.1.3 D-dimer
5.3.1.4 CK-MB
5.3.1.5 Myoglobin
5.3.1.6 Other cardiac market testing products
5.3.2 Blood gas/electrolytes testing products
5.3.3 HBA1C testing products
5.4 Infectious disease testing products
5.4.1 Influenza testing products
5.4.2 HIV testing products
5.4.3 Hepatitis C testing products
5.4.4 Sexually transmitted disease (STD) testing products
5.4.5 Healthcare-associated infection (HAI) testing products
5.4.6 Respiratory infection testing products
5.4.7 Tropical disease testing products
5.4.8 Other infectious disease testing products
5.5 Coagulation testing products
5.5.1 PT/INR testing products
5.5.2 Activated clotting time (ACT/APTT) testing products
5.6 Pregnancy and fertility testing products
5.6.1 Pregnancy testing products
5.6.2 Fertility testing products
5.7 Tumor/cancer marker testing products
5.8 Cholesterol testing products
5.9 Hematology testing products
5.10 Drug-of-abuse (DoA) testing products
5.11 Fecal occult testing products
5.12 Urinalysis testing products
5.13 Other products
Chapter 6 Primary Care POC Diagnostics Market Size and Forecast, By End-Use, 2018-2032 (USD Million)
6.1 Key trends, by end-use
6.2 Hospitals
6.3 Diagnostic centers
6.4 Research laboratories
6.5 Home-care settings
6.6 Other end-users
Chapter 7 Primary Care POC Diagnostics Market Size and Forecast, By Region, 2018-2032 (USD Million)
7.1 Key trends, by region
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 France
7.3.4 Italy
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Australia
7.4.5 South Korea
7.4.6 Rest of Asia Pacific
7.5 Latin America
7.5.1 Brazil
7.5.2 Mexico
7.5.3 Argentina
7.5.4 Rest of Latin America
7.6 Middle East and Africa
7.6.1 Saudi Arabia
7.6.2 South Africa
7.6.3 UAE
7.6.4 Rest of Middle East and Africa
Chapter 8 Company Profiles
8.1 Abbott Laboratories
8.2 ACON Laboratories, Inc.
8.3 Becton, Dickinson, and Company
8.4 BioMerieux SA
8.5 Bio-Rad Laboratories, Inc.
8.6 Dexcom, Inc.
8.7 Dragerwerk Ag & Co.
8.8 F. Hoffmann-La Roche
8.9 HemoCue AB (Danaher Corporation)
8.10 Nova Biomedical
8.11 Siemens Healthineers AG
8.12 Sysmex Corporation